ResearcherKarolinska University HospitalActive in the last 2 years

Linnéa Malgerud

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1691-0880; OpenAlex author ID A5052783041. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 19

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Carlos Fernández Moro · 2 shared papers, 2017–2024 · strength 0.24
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Matthias J. Löhr · 2 shared papers, 2017–2024 · strength 0.24
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Marco Del Chiaro · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Maximilian Kordes · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Raffaella Pozzi Mucelli · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Jan‐Erik Frödin · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Poya Ghorbani · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Mikael Björnstedt · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Maria Gustafsson Liljefors · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Nikolaos Kartalis · 1 shared paper, 2024 · strength 0.18
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070 ↗
Yunxia Lu · 2 shared papers, 2015–2016 · strength 0.12
- Paper Reply to 'Comment on 'New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic canc… DOI 10.1038/bjc.2016.100 ↗
- Paper New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. DOI 10.1038/bjc.2015.353 ↗
Jesper Lagergren · 2 shared papers, 2015–2016 · strength 0.12
- Paper Reply to 'Comment on 'New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic canc… DOI 10.1038/bjc.2016.100 ↗
- Paper New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. DOI 10.1038/bjc.2015.353 ↗
Tomas Sjöberg Bexelius · 2 shared papers, 2015–2016 · strength 0.12
- Paper Reply to 'Comment on 'New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic canc… DOI 10.1038/bjc.2016.100 ↗
- Paper New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. DOI 10.1038/bjc.2015.353 ↗
Rainer Lothar Heuchel · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Lars G. Engstrand · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Marco Del Chiaro · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Johan Permert · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Caroline Sophie Verbeke · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗
Markus J. Maeurer · 1 shared paper, 2017 · strength 0.05
- Paper Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. DOI 10.1002/1878-0261.12108 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.